Inhibition of angiogenesis and tumor growth by murine 7E3, the parent antibody of c7E3 Fab (abciximab; ReoPro™)

Angiogenesis

Volumn 3, Issue 1, 1999, Pages 53-60

  Varner, Judith A ^a   Nakada, Marian T ^b   Jordan, Robert E ^b   Coller, Barry S ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CENTOCOR INC   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

7E3; Angiogenesis; Integrin v 3; ReoPro

Indexed keywords

MURINAE;

EID: 0002588527     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009019223744     Document Type: Article

References (40)

1. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 1991; 64: 327.
2. Weinstat-Saslow D, Steeg PS. Angiogenesis and colonization in the tumor metastatic process: Basic and applied advances. FASEB J 1994; 8: 401.
3. Blood CH, Zetter BR. Tumor interactions with the vasculature: Angiogenesis and tumor metastasis. Biochim Biophys Acta 1990; 1032: 89.
4. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992; 3: 65.
5. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1.
6. Vartanian RK, Weidner N. Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma. Am J Pathol 1994; 144: 1188.
7. Weidner N, Folkman J, Pozza F et al. Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992; 84: 1875.
8. Gasparini G, Weidner N, Bevilacqua P et al. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 1994; 12: 454.
9. Gasparini G, Weidner N, Maluta S et al. Intratumoral microvessel density and p53 protein: Correlation with metastasis in head-and-neck squamous-cell carcinoma. Int J Cancer 1993; 55: 739.
10. O'Reilly MS, Holmgren L, Shing Y et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315.
11. O'Reilly MS, Boehm T, Shing Y et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277.
12. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279: 377.
13. Brooks PC, Montgomery AM, Rosenfeld M et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 1157.
14. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994; 264: 569.
15. Brooks PC, Stromblad S, Klemke R et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995; 96: 1815.
16. Friedlander M, Brooks PC, Shaffer RW et al. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995; 270: 1500.
17. Brown LF, Berse B, Jackman RW et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 1993; 143: 1255.
18. Brown LF, Berse B, Jackman RW et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995; 26: 86.
19. Leek RD, Harris AL, Lewis CE. Cytokine networks in solid human tumors: Regulation of angiogenesis. J Leukoc Biol 1994; 56: 423.
20. Hatva E, Kaipainen A, Mentula P et al. Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors. Am J Pathol 1995; 146: 368.
21. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992; 359: 845.
22. Smith DR, Polverini PJ, Kunkel SL et al. Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma. J Exp Med 1994; 179: 1409.
23. Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841.
24. Enenstein J, Waleh NS, Kramer RH. Basic FGF and TGF-beta differentially modulate integrin expression of human microvascular endothelial cells. Exp Cell Res 1992; 203: 499.
25. Enenstein J, Kramer RH. Confocal microscopic analysis of integrin expression on the microvasculature and its sprouts in the neonatal foreskin. J Invest Dermatol 1994; 103: 381.
26. Sepp NT, Li LJ, Lee KH et al. Basic fibroblast growth factor increases expression of the alpha v beta 3 integrin complex on human microvascular endothelial cells. J Invest Dermatol 1994; 103: 295.
27. Stromblad S, Becker JC, Yebra M et al. Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. J Clin Invest 1996; 98: 426.
28. Brooks PC, Stromblad S, Sanders LC et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996; 85: 683.
29. Brooks PC, Silletti S, von Schalscha TL et al. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998; 92: 391.
30. Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet GPIIb/IIIa complex. J Clin Invest 1985; 76: 101.
31. Coller BS, Scudder LE, Beer J et al. Monoclonal antibodies to platelet GPIIb/IIIa as antithrombotic agents. Ann NY Acad Sci 1991; 614: 193.
32. Coller BS. Platelet GPIIb/IIIa antagonists: The first anti-integrin receptor therapeutics. J Clin Invest 1997; 99: 1467.
33. Coller BS, Cheresh DA, Asch E, Seligsohn U. Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann thrombasthenia in Israel. Blood 1991; 77: 75.
34. 3 integrins. Circulation 1998; 98: 1086.
35. Newman PJ, McEver RP, Doers MP, Kunicki TJ. Synergistic action of two murine monoclonal antibodies that inhibit ADP-induced platelet aggregation without blocking fibrinogen binding. Blood 1987; 69: 668.
36. Newman PJ. The biology of PECAM-1. J Clin Invest 1997; 99: 3.
37. Felding-Habermann B, Mueller BM, Romerdahl CA, Cheresh DA. Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. J Clin Invest 1992; 89: 2018.
38. Friedlander M, Theesfeld CL, Sugita M et al. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc Natl Acad Sci USA 1996; 93: 9764.
39. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689.
40. Karpatkin SE, Pearlstein C, Ambrogio C, Coller BS. Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J Clin Invest 1987; 81: 1012.